According to a new study published in the journal Science, scientists may be one step closer to stopping drug-resistant tumors from growing. The study, conducted by a team of researchers at the University of California, San Francisco, used a new approach to target a specific protein that helps drug-resistant tumors to grow.
The protein, called STAT3, is a key regulator of cell growth and is frequently mutated in a variety of human cancers. In the study, the researchers used a new approach to target STAT3, which involved targeting a specific amino acid that is essential for the protein’s function.
By targeting this amino acid, the researchers were able to stop the growth of drug-resistant tumors in mice. This new approach could potentially be used to treat a variety of drug-resistant cancers in humans.
The study’s lead author, UCSF postdoctoral fellow Wei Zhang, PhD, said that the findings suggest that this new approach could be used to effectively target drug-resistant tumors. “This study provides proof-of-concept that targeting a specific amino acid residue is a viable strategy for overcoming cancer drug resistance,” Zhang said. “We are hopeful that this approach will lead to the development of new cancer therapeutics.”
In a new study, published in the journal Nature, scientists have found a way to stop drug-resistant tumors from growing. This is a significant step forward in the fight against cancer.
Cancer is a leading cause of death worldwide, and one of the biggest challenges in treating the disease is the development of drug resistance. When cancer cells become resistant to a treatment, it can make the disease difficult to control.
In the new study, the scientists used a technique called CRISPR-Cas9 to target a gene that helps drug-resistant tumors to grow. By disabling this gene, they were able to stop the tumors from growing.
This is an important discovery that could lead to new treatments for cancer that are more effective and less likely to cause resistance. It is also a reminder of the power of CRISPR-Cas9, which is a relatively new tool that is being used to study a variety of diseases.